Monocyte and M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD

Donata Lissner(Charité - Universitätsmedizin Berlin), Britta Siegmund(Humboldt-Universität zu Berlin)

Inflammatory Bowel Diseases

April 1, 2015

10.1097/mib.0000000000000384

Cited by 361

Related Papers

Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans

|Cell|2019|472

An Integrated Taxonomy for Monogenic Inflammatory Bowel Disease

|Gastroenterology|2021|94

Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects

|Frontiers in Immunology|2017|69

Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study

|Journal of Crohn s and Colitis|2025|10

P0636 Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study

|Journal of Crohn s and Colitis|2025|1